Search Results
Efficacy of anti-myeloma therapies following relapse on idecabtagene vicleucel
KarMMa2: Efficacy and Safety of Idecabtagene Vicleucel in HRMM Pts with Early Relapse after ASCT
Idecabtagene Vicleucel in Pts with Relapsed and Refractory Multiple Myeloma: Updated KarMMa Results
Idecabtagene vicleucel for relapsed and refractory multiple myeloma
Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MD
KarMMa: idecabtagene vicleucel QoL
Idecabtagene vicleucel for R/R myeloma
KarMMa-3: Phase III trial of idecabtagene vicleucel in R/R myeloma
Dr. Morgan on Idecabtagene Vicleucel in Multiple Myeloma
ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa results
Relapsed Therapy and Clinical Trials - Dr. Caitlin Costello: RCW San Diego 2021
Hitting the BCMA Target in Multiple Myeloma
